FILE PHOTO: The logo of Swiss drugmaker Novartis is seen at the company's new cell and gene therapy factory in Stein, Switzerland, November 28, 2019.Arnd Wiegmann | ReutersNovartis shares tanked 10% on Tuesday after the pharmaceutical giant said its del-desiran drug for muscle-wasting disorder failed in a late-stage trial. The company's stock was last seen down by 10%, as investors reacted to what was its third drug trial setback in a week. Stock Chart IconStock chart iconNovartis stockThis is a developing story. Please refresh for updates.
Pharma major plummets over 10% after third trial disappointment in a week
Full Article
Original Source
Read the full article at Cnbc →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.